Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance

This article was originally published here

Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will

The post Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply